Literature DB >> 31779842

Are there new targets for juvenile idiopathic arthritis?

Alberto Martini1.   

Abstract

Juvenile idiopathic arthritis (JIA) is not a disease but an umbrella term that gather all forms of chronic arthritis of unknown origin and with onset in childhood. Some of these disorders appear to be the childhood equivalent of adult diseases and share therefore the same therapeutic targets. A form characterized by early onset and antinuclear antibody positivity seems to be specific for children but further evidence is needed. Systemic JIA (sJIA), although equivalent to adult onset Still disease is much more frequent in childhood. Novel potential targets for sJIA as well as for macrophage activation syndrome, its more severe complication, have therefore been investigated mainly in children.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Classification; IFN-γ; IL-1; IL-18; IL-6; Juvenile idiopathic arthritis

Mesh:

Substances:

Year:  2019        PMID: 31779842     DOI: 10.1016/j.semarthrit.2019.09.017

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  3 in total

Review 1.  Juvenile idiopathic arthritis.

Authors:  Alberto Martini; Daniel J Lovell; Salvatore Albani; Hermine I Brunner; Kimme L Hyrich; Susan D Thompson; Nicolino Ruperto
Journal:  Nat Rev Dis Primers       Date:  2022-01-27       Impact factor: 65.038

2.  Identification of Key Biomarkers and Immune Infiltration in Systemic Juvenile Idiopathic Arthritis by Integrated Bioinformatic Analysis.

Authors:  Min Zhang; Rongxin Dai; Qin Zhao; Lina Zhou; Yunfei An; Xuemei Tang; Xiaodong Zhao
Journal:  Front Mol Biosci       Date:  2021-07-14

Review 3.  Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches.

Authors:  Lina N Zaripova; Angela Midgley; Stephen E Christmas; Michael W Beresford; Eileen M Baildam; Rachel A Oldershaw
Journal:  Pediatr Rheumatol Online J       Date:  2021-08-23       Impact factor: 3.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.